Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cyto-toxicity. Found 20 abstracts

Lewis-Wambi JS, Swaby R, Kim H, Jordan VC. Potential of L-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2009 Mar;114(1-2):33-9.   PMCID: PMC28689080
Yao K, Gietema JA, Shida S, Selvakumaran M, Fonrose X, Haas NB, Testa J, O'Dwyer PJ. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. British Journal of Cancer. 2005 Dec 12;93(12):1356-63.
Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, O'Dwyer PJ. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochemical pharmacology. 2002 May;63(9):1699-707.
Ozols R. Treatment of gynecologic cancer: The US experience. Tumori. 1999 May;85(3):S5-S11.
Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Research. 1999 Aug;59(15):3663-70.
Calvert P, Yao KS, Hamilton TC, O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione. Chemico-Biological Interactions. 1998 Apr 24;112:213-24.
Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resistance Updates. 1998 Jan;1(4):243-54.
Yao KS, Hageboutros A, Ford P, Odwyer PJ. Involvement of activator protein-1 and nuclear factor-kappa B transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Molecular Pharmacology. 1997 Mar;51(3):422-30.
Odwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of Clinical Oncology. 1996 Jan;14(1):249-56.
Krigel RL, Padavicshaller K, Toomey C, Comis RL, Weiner LM. Phase-I Study of Sequentially Administered Recombinant Tumor- Necrosis-Factor and Recombinant Interleukin-2. Journal of Immunotherapy. 1995 Apr;17(3):161-70.
Lacreta FP, Brennan JM, Hamilton TC, Ozols RF, Odwyer PJ. Stereoselective Pharmacokinetics of L-Buthionine Sr-Sulfoximine in Patients with Cancer. Drug Metabolism and Disposition. 1994 Nov;22(6):835-42.
Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK. Phase-I Trial of Recombinant Macrophage-Colony-Stimulating Factor and Recombinant Gamma-Interferon - Toxicity, Monocytosis, and Clinical Effects. Cancer Research. 1994 Aug;54(15):4084-90.
Brennan JM, Odwyer PJ, Ozols RF, Lacreta FP. High-Performance Liquid-Chromatographic Determination of the S- Diastereoisomers and R-Diastereoisomers of L-Buthionine (Sr)- Sulfoximine in Human Plasma and Urine. Journal of Chromatography-Biomedical Applications. 1993 Oct 22;620(1):121-8.
Ciaccio PJ, Stuart JE, Tew KD. Overproduction of a 37.5-Kda Cytosolic Protein Structurally Related to Prostaglandin-F Synthase in Ethacrynic Acid- Resistant Human Colon Cells. Molecular Pharmacology. 1993 Jun;43(6):845-53.
Depalazzo IG, Kitson J, Gerceltaylor C, Adams S, Weiner LM. Bispecific Monoclonal-Antibody Regulation of Fc-Gamma-Riii- Directed Tumor-Cytotoxicity by Large Granular Lymphocytes. Cellular Immunology. 1992 Jul;142(2):338-47.
Hamilton TC. Ovarian-Cancer 1. Biology. Current Problems in Cancer. 1992 Jan;16(1):5-57.
Ozols RF. Role of Chemotherapy in the Future Treatment of Ovarian-Cancer. Acta Obstetricia Et Gynecologica Scandinavica. 1992 Jan;71:55-60.
Ozols RF. Advances in the Chemotherapy of Gynecologic Malignancies. Hematological Oncology. 1992 Jan;10(1):43-51.
Perez RP, Handel LM, Hamilton TC. Potentiation of Cisplatin Cytotoxicity in Human Ovarian- Carcinoma Cell-Lines by Trifluoperazine, a Calmodulin Inhibitor. Gynecologic Oncology. 1992 Jul;46(1):82-7.
Tew KD, Glusker JP, Hartleyasp B, Hudes G, Speicher LA. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacology & Therapeutics. 1992 Jan;56(3):323-39.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cyto-toxicity

cyto-toxicity tumor-cells melphalan depletion cell-lines carcinoma resistant glutathione l-phenylalanine mustard dna-repair carcinoma cell-lines cisplatin alkylating-agents ovarian-cancer sulfoximine drug-resistant potent repair mammalian-cells mice human ovarian-cancer glutathione synthesis expression hypoxia chemotherapy drug resistance cytotoxicity therapy buthionine sulfoximine dose intensity surface epithelium gene- cell-adhesion molecule clinical-trial cancer cell-lines breast-cancer responsive element growth receptors drug- dna- microtubule assembly invitro apoptosis electrophiles multidrug resistance multidrug-resistance tumor necrosis factor antisense cancer gene radiation sensitizer cisplatin sensitivity cervical-cancer ifosfamide colon cancer derivatization solid tumors p53 function follicle rupture activated killer cells (sr)-sulfoximine xanthine dehydrogenase intraperitoneal cisplatin taxol lung-cancer s-transferase activity antioxidant response element ovarian cancer glutathione transferases brain microtubules phase i study ap-1 gynecologic oncology group carboplatin gamma-interferon oncology-group d synthetase interleukin-2 p-glycoprotein lesions regulatory elements reductive activation colorectal-carcinoma ISIS 10582 mouse phase-i factor-alpha prostate-cancer ya-subunit gene fc-receptors nuclear in- invitro prostatic-carcinoma controlling inducible expression estrogen deprivation intracellular glutathione c-Jun nitrogen mustards vitro growth-factor angiogenesis buthionine s-transferase homeostasis p53 modulation damage cis-diamminedichloroplatinum(ii) dose interleukin-2 refractory dna mismatch repair human peripheral-blood germinal epithelium prior dna-binding antitumor- paclitaxel accumulation hamster ovary cells cross-resistance nucleotide excision- estracyt prototypic hereditary neoplasm randomized surface antibody induced ovulation malignancy inhibition antagonists pharmacokinetics subunit gene rapid intravenous-infusion tumor-cell melanoma glutathione depletion activator protein-1 intraperitoneal chemotherapy enhanced dna-repair antigen bovine lung trial proliferation advanced cancer bioactivation protein-kinase Low dose estrogen therapy Antihormone resistance-Apoptosis-Breast cancer-L-Buthionine sulfoximine-Glutathione activity combination therapy bone-marrow support
Last updated on Wednesday, February 05, 2020